Hyderabad: The anti-narcotics bureau busted a high-end party at Madhapur and subjected guests to on-the-spot drugs tests out of which 8 tested positive for a range of drugs including marijuana, ...

Regeneron Pharmaceuticals has announced positive Phase 2 results for two investigational monoclonal antibodies, REGN7508 and REGN9933, which target different domains of Factor XI to control ...

(NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Factor XI. REGN7508 (catalytic domain) is designed to maximize ...

“Ana was a force of nature,” he continued. “I keep thinking about how at times, I'd make a self-deprecating joke and she'd snap ‘Hey! Don't talk about my friend like that!’ Her genuine ...

An Arizona TV station is mourning the death of one of its anchors. Ana Orsini, 28, a morning anchor at KOLD 13 News in Tucson, Arizona, died from a brain aneurysm, according to the station.

please donate to your local animal shelter–Ana never met a dog she didn't love!" Orsini had an overwhelmingly positive impact on those around her, which has been further proven by her colleagues ...

Ana Orsini, a local television anchor at CBS affiliate KOLD-TV in Tucson, Arizona, died last week at the age of 28, her colleagues announced during a broadcast Monday. "Our beloved friend and co ...

CBS affiliate KOLD-TV announced on Monday, Dec. 16, that the 28-year-old Arizona news anchor died last week Ana Orsini/Facebook Ana Orsini, the 28-year-old Arizona news anchor who died last week ...

News anchor Ana Orsini died unexpectedly last week, according to her colleagues. Tyler Butler/13 News/KOLD via Facebook Ana Orsini, a local news anchor in Tucson, Arizona, has died at age 28 ...

A Tucson TV station is mourning the sudden death of one of its anchors. Ana Orsini, 28, a morning anchor at KOLD 13 News in Tucson, died from a brain aneurysm, according to the station.

Sanofi and Teva are closing the gap with positive data on their own anti-TL1A antibody duvakitug. In the phase 2b RELIEVE UCCD trial, duvakitug met the mark in patients with ulcerative colitis (UC ...